Bioatla Documents
Documents
100
Ticker
BCAB
ISIN
US09077B1044
Bioatla SEC Filings
Bioatla Documents 2026
This page contains all official documents and SEC filings for Bioatla stock (BCAB, ISIN: US09077B1044). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of Bioatla's regulatory filings.
Bioatla Stock analysis
Bioatla Bioatla Inc, trading under ticker BCAB, is a US-based biotechnology company headquartered in San Diego. It operates in the Health Care sector with a focus on developing antibody-based therapeutics for solid tumor cancers. The company has 66 employees and completed an IPO on December 16, 2020. Its product pipeline includes BA3011, a conditionally active biologics antibody-drug conjugate targeting AXL, and BA3021, targeting ROR2. Other candidates are BA3071, an anti-CTLA-4 antibody, and BA3182, a dual-CAB therapy for adenocarcinoma.